131 related articles for article (PubMed ID: 38376289)
21. MELK aggravates lung adenocarcinoma by regulating EZH2 ubiquitination and H3K27me3 histone methylation of LATS2.
Yu H; Xu X; Zhu L; Chen S; He J
J Cell Mol Med; 2024 Apr; 28(8):e18216. PubMed ID: 38652219
[TBL] [Abstract][Full Text] [Related]
22. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
23. Potential Diagnostic and Prognostic Values of CBX8 Expression in Liver Hepatocellular Carcinoma, Kidney Renal Clear Cell Carcinoma, and Ovarian Cancer: A Study Based on TCGA Data Mining.
Lin J; Chen L; Wu D; Lin J; Liu B; Guo C
Comput Math Methods Med; 2022; 2022():1372879. PubMed ID: 35813444
[TBL] [Abstract][Full Text] [Related]
24. ASPM Is a Prognostic Biomarker and Correlates With Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma.
Deng T; Liu Y; Zhuang J; Tang Y; Huo Q
Front Oncol; 2022; 12():632042. PubMed ID: 35515103
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
[TBL] [Abstract][Full Text] [Related]
26. MELK is Upregulated in Advanced Clear Cell Renal Cell Carcinoma and Promotes Disease Progression by Phosphorylating PRAS40.
Zhang H; Wei P; Lv W; Han X; Yang J; Qin S; Zhang Y
Cell Transplant; 2019 Dec; 28(1_suppl):37S-50S. PubMed ID: 31813279
[TBL] [Abstract][Full Text] [Related]
27. Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer.
Sial N; Saeed S; Ahmad M; Hameed Y; Rehman A; Abbas M; Asif R; Ahmed H; Hussain MS; Rehman JU; Atif M; Khan MR
Int J Gen Med; 2021; 14():7025-7042. PubMed ID: 34707394
[TBL] [Abstract][Full Text] [Related]
28. Decoding the DSCC1 gene as a pan-cancer biomarker in human cancers via comprehensive multi-omics analyses.
Wang J; Gilani SF; Noor N; Ahmed MR; Munazir M; Zubair A; Sultan R; Abdel-Maksoud MA; Saleh IA; Zomot N; Kodous AS; Ibrahim SS; El-Tayeb MA; Aufy M; Zaky MY; Hassan SS; Hameed Y
Am J Transl Res; 2024; 16(3):738-754. PubMed ID: 38586115
[TBL] [Abstract][Full Text] [Related]
29. Identifies microtubule-binding protein
Wang W; Zhang J; Wang Y; Xu Y; Zhang S
Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
[TBL] [Abstract][Full Text] [Related]
30. Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers.
Dong X; Liu T; Li Z; Zhai Y
Aging (Albany NY); 2023 Jul; 15(14):7237-7257. PubMed ID: 37498296
[TBL] [Abstract][Full Text] [Related]
31. ELL associated factor 2 is a potential diagnostic and prognostic indicator: evidence from the in silico and in vitro experiments.
Yu X; Teng JQ; Chen J; Peng C; Guo TR; Dong MW; Hao XL; Li KX; Huo XX; Ren CC
Am J Cancer Res; 2023; 13(6):2572-2587. PubMed ID: 37424805
[TBL] [Abstract][Full Text] [Related]
32. Stromal Interaction Molecule 1 (STIM1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Solid Tumors.
Zhang Z; Wang Z; Liu Y; Zhao L; Fu W
J Environ Pathol Toxicol Oncol; 2023; 42(2):11-30. PubMed ID: 36749087
[TBL] [Abstract][Full Text] [Related]
33. A pan-cancer analysis of the prognostic implication and oncogenic role of tubulin epsilon and delta complex 2 (TEDC2) in human tumors.
Liu Y; Zhu J; Shen J; Lu Y; Pan K; Tong C; Wang Y
Front Immunol; 2023; 14():1272108. PubMed ID: 38239349
[TBL] [Abstract][Full Text] [Related]
34. System analysis of
Situ Y; Xu Q; Deng L; Zhu Y; Gao R; Lei L; Shao Z
Int J Biol Markers; 2022 Mar; 37(1):90-101. PubMed ID: 34870494
[TBL] [Abstract][Full Text] [Related]
35. Maternal embryonic leucine zipper kinase (MELK): a novel regulator in cell cycle control, embryonic development, and cancer.
Jiang P; Zhang D
Int J Mol Sci; 2013 Oct; 14(11):21551-60. PubMed ID: 24185907
[TBL] [Abstract][Full Text] [Related]
36. Maternal embryonic leucine zipper kinase in tumor cells and tumor microenvironment: An emerging player and promising therapeutic opportunity.
Tang BF; Yan RC; Wang SW; Zeng ZC; Du SS
Cancer Lett; 2023 Apr; 560():216126. PubMed ID: 36933780
[TBL] [Abstract][Full Text] [Related]
37. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
38. DHX37 Impacts Prognosis of Hepatocellular Carcinoma and Lung Adenocarcinoma through Immune Infiltration.
Xu Y; Jiang Q; Liu H; Xiao X; Yang D; Saw PE; Luo B
J Immunol Res; 2020; 2020():8835393. PubMed ID: 33490290
[TBL] [Abstract][Full Text] [Related]
39. MELK is an oncogenic kinase essential for metastasis, mitotic progression, and programmed death in lung carcinoma.
Tang Q; Li W; Zheng X; Ren L; Liu J; Li S; Wang J; Du G
Signal Transduct Target Ther; 2020 Dec; 5(1):279. PubMed ID: 33262323
[TBL] [Abstract][Full Text] [Related]
40. Expression of Maternal Embryonic Leucine Zipper Kinase (MELK) Correlates to Malignant Potentials in Hepatocellular Carcinoma.
Hiwatashi K; Ueno S; Sakoda M; Iino S; Minami K; Yonemori K; Nishizono Y; Kurahara H; Mataki Y; Maemura K; Shinchi H; Natsugoe S
Anticancer Res; 2016 Oct; 36(10):5183-5188. PubMed ID: 27798878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
